Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
“We are delighted to have the backing of these sophisticated investors as we strive to develop novel immunotherapies that can provide durable clinical benefit for broad populations of cancer patients,” said Kevin Pojasek, Ph.D., President & Chief Executive Officer of Enara Bio. “Earlier this year, our EDAPT platform received strong external validation when Boehringer Ingelheim decided to exercise its option to license multiple Dark Antigens to develop off-the-shelf immunotherapies for lung cancer. The fundraise we are announcing today, led by two new strategic investors, reflects the quality of our science and further underlines not only the groundbreaking potential of Dark Antigens, but also our internal pipeline of first-in-class immunotherapies.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us